Barrie J Carter

Author PubWeight™ 28.04^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Effect of gene therapy on visual function in Leber's congenital amaurosis.	N Engl J Med	2008	15.30
2	Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi.	Proc Natl Acad Sci U S A	2008	4.53
3	Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice.	Mol Ther	2009	2.47
4	AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.	Mol Ther	2004	1.55
5	Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial.	Hum Gene Ther	2007	1.47
6	A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies.	Hum Gene Ther	2002	1.40
7	Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study.	Hum Gene Ther	2003	1.36
8	Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy.	Hum Gene Ther	2005	0.88
9	Nonclinical toxicology in support of licensure of gene therapies. Arlington, VA, USA, March 13-14, 2003.	Mol Ther	2003	0.75
10	Workshop on long-term follow-up of participants in human gene transfer research.	Mol Ther	2004	0.75